# Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)

> **NCT04608214** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 26 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **DRUG:** Alisporivir
- **OTHER:** Standard of care (SOC)

## Key facts

- **NCT ID:** NCT04608214
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-08
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-04-13
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608214, "Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT04608214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*